Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$100.06
-1.4%
$91.23
$73.04
$121.90
$6.56B0.83781,125 shs709,926 shs
Certara, Inc. stock logo
CERT
Certara
$11.55
+1.1%
$11.82
$8.64
$17.76
$1.87B1.571.33 million shs1.12 million shs
Omnicell, Inc. stock logo
OMCL
Omnicell
$29.61
+4.9%
$30.70
$22.66
$55.75
$1.39B0.78565,477 shs689,821 shs
Prothena Co. plc stock logo
PRTA
Prothena
$4.58
-30.4%
$9.38
$4.45
$25.42
$246.53M0.11639,124 shs9.65 million shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-1.42%-2.85%+14.15%+9.47%-2.67%
Certara, Inc. stock logo
CERT
Certara
+1.14%-1.20%-18.49%-6.33%-30.96%
Omnicell, Inc. stock logo
OMCL
Omnicell
+4.89%+2.88%-4.36%-25.47%-9.26%
Prothena Co. plc stock logo
PRTA
Prothena
-30.40%-37.17%-52.78%-68.52%-77.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
2.6008 of 5 stars
4.41.00.00.02.90.80.6
Certara, Inc. stock logo
CERT
Certara
4.5739 of 5 stars
4.31.00.04.33.11.71.9
Omnicell, Inc. stock logo
OMCL
Omnicell
3.1226 of 5 stars
4.32.00.00.02.21.71.3
Prothena Co. plc stock logo
PRTA
Prothena
3.2865 of 5 stars
4.23.00.00.02.11.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
2.83
Moderate Buy$126.5626.49% Upside
Certara, Inc. stock logo
CERT
Certara
2.63
Moderate Buy$15.6735.64% Upside
Omnicell, Inc. stock logo
OMCL
Omnicell
2.57
Moderate Buy$44.8351.41% Upside
Prothena Co. plc stock logo
PRTA
Prothena
2.44
Hold$31.50587.77% Upside

Current Analyst Ratings Breakdown

Latest OMCL, PRTA, CERT, and BPMC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Prothena Co. plc stock logo
PRTA
Prothena
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.00
5/27/2025
Prothena Co. plc stock logo
PRTA
Prothena
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.00
5/27/2025
Prothena Co. plc stock logo
PRTA
Prothena
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral
5/27/2025
Prothena Co. plc stock logo
PRTA
Prothena
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$6.00
5/27/2025
Prothena Co. plc stock logo
PRTA
Prothena
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
5/27/2025
Prothena Co. plc stock logo
PRTA
Prothena
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $14.00
5/27/2025
Prothena Co. plc stock logo
PRTA
Prothena
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $18.00
5/23/2025
Omnicell, Inc. stock logo
OMCL
Omnicell
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/23/2025
Omnicell, Inc. stock logo
OMCL
Omnicell
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$30.00 ➝ $34.00
5/23/2025
Omnicell, Inc. stock logo
OMCL
Omnicell
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$35.00 ➝ $37.00
5/14/2025
Omnicell, Inc. stock logo
OMCL
Omnicell
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$31.00 ➝ $35.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$562.12M11.50N/AN/A$4.67 per share21.43
Certara, Inc. stock logo
CERT
Certara
$394.50M4.75$0.81 per share14.32$6.55 per share1.76
Omnicell, Inc. stock logo
OMCL
Omnicell
$1.14B1.22$2.29 per share12.95$26.84 per share1.10
Prothena Co. plc stock logo
PRTA
Prothena
$137.94M1.79N/AN/A$10.46 per share0.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$67.09M-$2.47N/A153.94N/A-13.19%-77.49%-20.84%8/7/2025 (Estimated)
Certara, Inc. stock logo
CERT
Certara
-$55.36M-$0.02N/A32.089.29-8.34%3.43%2.33%8/5/2025 (Estimated)
Omnicell, Inc. stock logo
OMCL
Omnicell
$12.53M$0.46109.6723.887.531.13%3.82%2.07%8/7/2025 (Estimated)
Prothena Co. plc stock logo
PRTA
Prothena
-$147.03M-$2.08N/AN/AN/A-90.50%-22.67%-19.68%8/14/2025 (Estimated)

Latest OMCL, PRTA, CERT, and BPMC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Prothena Co. plc stock logo
PRTA
Prothena
-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million
5/6/2025Q1 2025
Omnicell, Inc. stock logo
OMCL
Omnicell
$0.16$0.26+$0.10-$0.15$260.18 million$269.67 million
5/5/2025Q1 2025
Certara, Inc. stock logo
CERT
Certara
$0.10$0.14+$0.04$0.03$104.44 million$106.00 million
5/1/2025Q1 2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
Certara, Inc. stock logo
CERT
Certara
N/AN/AN/AN/AN/A
Omnicell, Inc. stock logo
OMCL
Omnicell
N/AN/AN/AN/AN/A
Prothena Co. plc stock logo
PRTA
Prothena
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
1.15
2.85
2.80
Certara, Inc. stock logo
CERT
Certara
0.28
2.86
2.86
Omnicell, Inc. stock logo
OMCL
Omnicell
0.13
1.37
1.22
Prothena Co. plc stock logo
PRTA
Prothena
N/A
11.52
11.52

Institutional Ownership

CompanyInstitutional Ownership
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/A
Certara, Inc. stock logo
CERT
Certara
73.96%
Omnicell, Inc. stock logo
OMCL
Omnicell
97.70%
Prothena Co. plc stock logo
PRTA
Prothena
97.08%

Insider Ownership

CompanyInsider Ownership
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
4.21%
Certara, Inc. stock logo
CERT
Certara
2.33%
Omnicell, Inc. stock logo
OMCL
Omnicell
2.52%
Prothena Co. plc stock logo
PRTA
Prothena
9.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
64064.58 million61.22 millionOptionable
Certara, Inc. stock logo
CERT
Certara
350162.23 million157.14 millionOptionable
Omnicell, Inc. stock logo
OMCL
Omnicell
3,80046.84 million45.09 millionOptionable
Prothena Co. plc stock logo
PRTA
Prothena
13053.83 million38.64 millionOptionable

Recent News About These Companies

Why Is Prothena Stock Trading Lower On Tuesday?
Prothena slumps on Phase III birtamimab miss

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Blueprint Medicines stock logo

Blueprint Medicines NASDAQ:BPMC

$100.06 -1.44 (-1.42%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$100.08 +0.02 (+0.02%)
As of 05/27/2025 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Certara stock logo

Certara NASDAQ:CERT

$11.55 +0.13 (+1.14%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$11.65 +0.10 (+0.87%)
As of 05/27/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Omnicell stock logo

Omnicell NASDAQ:OMCL

$29.61 +1.38 (+4.89%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$29.60 0.00 (-0.02%)
As of 05/27/2025 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Prothena stock logo

Prothena NASDAQ:PRTA

$4.58 -2.00 (-30.40%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.62 +0.04 (+0.87%)
As of 05/27/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.